NasdaqGM:HRMYPharmaceuticals
Is Harmony Biosciences (HRMY) Quietly Recasting Its Single-Drug Story Into a Broader Neuroscience Platform?
Harmony Biosciences has recently outlined plans to expand beyond its core sleep drug Wakix by advancing pitolisant into new indications, developing high-dose and gastro-resistant formulations, and progressing additional neuroscience assets such as an orexin-2 receptor agonist and rare epilepsy programs.
This push to diversify its portfolio suggests Harmony is working to reduce its reliance on a single product and build a broader neuroscience franchise across sleep and rare neurological...